Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Acute Myeloid Leukemia AML Market Analyze the dynamic Acute Myeloid Leukemia (AML) market, driven by innovations in therapies and growin ...

While Pfizer has made a number of acquisitions, its biggest bet is on Seagen. Pfizer wants this to be a transformative ...

Tencent Health and Pfizer China have launched the "Pfizer Smart Healthcare Innovation Ecosystem" at the "Tides of Qiantang" Conference. This collaboration aims to drive innovation in smart healthcare ...

Bourla and Shantanu Narayen, Pfizer's lead independent director and Adobe Systems CEO, will hold talks with Starboard chief ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, both of whom expressed interest in supporting the activist investor's ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Shares of Pfizer PFE rose 2.17% on Oct. 7 after a report from The Wall Street Journal stated that activist investor Starboard ...

Pfizer Inc.’s stock gained Monday after a report that activist investor Starboard Value has invested $1 billion in the drug ...

Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Pfizer is in value territory, trading at just 10.74X forward earnings with a 5.88% annual dividend yield and over $10 billion in cash after selling $2.4 billion of its HLN position.